STEERING PROGRESS,
SHAPING THE FUTURE
Our ability to utilise expertise and consolidate university-led research, plant genetics programs, cannabinoid research, selective breeding programs, proprietary cultivation techniques and drug development pathways will offer long-term industry engagement and academic contribution and progression.
Our collaboration with Deakin University allows Medigrowth to contribute to multidisciplinary, innovative research that will shape the future. Industry partnership and university-led Australian Research Council initiatives allow Medigrowth to be an active player in industry development and discovery.
MEDIGROWTH AND DEAKIN UNIVERSITY:
Innovation, collaboration AND world class research
Medigrowth is committed to advancing cannabinoid science and research. The Deakin-Medigrowth relationship is anchored in collaboration and commitment to world class research with real world outcomes via plant science, translational research initiatives and implementation of joint PhD programs and postgraduate training. We share an exciting future together as we collectively develop and explore the scientific and therapeutic potential of cannabinoids and full-spectrum cannabis extracts.
-
Effects of Cannabidiol in Children with Autism (CBDCA) (DUHREC 071_2022): Completed
Effects of Cannabidiol on Social Relating, Anxiety, and Parental Stress in Autistic Children: A Randomised Controlled Crossover Trial (preprint; under peer review for publication).
Cannabidiol Modulates Right Fronto-Parietal Connectivity in Autistic Children: A Secondary EEG Analysis from a Randomised Placebo-Controlled Crossover Trial (preprint; under peer review for publication).
-
Medigrowth Longitudinal Observational Study (DUHEAG 166_2022): Ongoing, recruiting until May 2026.
The EMPOWER Project: Evaluating Medigrowth patient outcomes for mental wellbeing, efficacy and safety in the real world (2025/HE000503): Not yet started, under ethics review.
